Treatment of a pregnant woman with an angiotensin receptor blocking (ARB) agent can result in a number of changes in the fetus termed the ARB fetopathy. The findings are similar those seen with angiotensin converting enzyme (ACE) inhibitors. Therapy with an ARB is contraindicated during pregnancy.